MX2020008702A - Metodos para la deteccion y tratamiento del cancer de prostata. - Google Patents
Metodos para la deteccion y tratamiento del cancer de prostata.Info
- Publication number
- MX2020008702A MX2020008702A MX2020008702A MX2020008702A MX2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- prostate cancer
- treatment
- cancer detection
- prostate
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633675P | 2018-02-22 | 2018-02-22 | |
| PCT/US2019/018878 WO2019165021A1 (en) | 2018-02-22 | 2019-02-21 | Methods for prostate cancer detection and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008702A true MX2020008702A (es) | 2020-09-25 |
Family
ID=65686083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008702A MX2020008702A (es) | 2018-02-22 | 2019-02-21 | Metodos para la deteccion y tratamiento del cancer de prostata. |
| MX2025000449A MX2025000449A (es) | 2018-02-22 | 2020-08-20 | Metodos in vitro para la deteccion del cancer de prostata |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025000449A MX2025000449A (es) | 2018-02-22 | 2020-08-20 | Metodos in vitro para la deteccion del cancer de prostata |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11410748B2 (https=) |
| EP (2) | EP3755816B1 (https=) |
| JP (2) | JP7662337B2 (https=) |
| KR (2) | KR102921718B1 (https=) |
| CN (2) | CN119932188A (https=) |
| AU (2) | AU2019224025B2 (https=) |
| BR (1) | BR112020016989A2 (https=) |
| CA (1) | CA3091647A1 (https=) |
| DK (1) | DK3755816T3 (https=) |
| ES (1) | ES3023842T3 (https=) |
| IL (1) | IL276748A (https=) |
| MX (2) | MX2020008702A (https=) |
| PL (1) | PL3755816T3 (https=) |
| SG (1) | SG11202007922XA (https=) |
| WO (1) | WO2019165021A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022004372A (es) | 2019-10-10 | 2022-07-27 | Liquid Biopsy Res Llc | Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn. |
| EP4100955A4 (en) * | 2020-02-06 | 2024-02-28 | Oncohost Ltd | MACHINE LEARNING PREDICTION OF THERAPEUTIC RESPONSE |
| CA3227993A1 (en) | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
| EP4602184A1 (en) * | 2022-10-12 | 2025-08-20 | Liquid Biopsy Research LLC | Methods for prostate cancer detection in saliva |
| GB2623570B (en) * | 2022-10-21 | 2025-07-23 | Wobble Genomics Ltd | Method and products for biomarker identification |
| KR102891032B1 (ko) * | 2022-12-29 | 2025-12-03 | 재단법인대구경북과학기술원 | 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도 |
| CN116908444B (zh) * | 2023-09-13 | 2023-12-19 | 中国医学科学院北京协和医院 | 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用 |
| CN119964650B (zh) * | 2024-12-24 | 2025-09-30 | 深圳大学 | 一种基于集成学习的基因调控网络推断方法和系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009540852A (ja) * | 2006-07-03 | 2009-11-26 | エグゾニ・テラピューティック・ソシエテ・アノニム | 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 |
| US20100303795A1 (en) * | 2009-05-27 | 2010-12-02 | Soerensen Karina Dalsgaard | Marker of prostate cancer |
| MX338883B (es) * | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| US8725426B2 (en) | 2012-01-31 | 2014-05-13 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| CA2879557A1 (en) * | 2012-07-20 | 2014-01-23 | Diagnocure Inc. | Methods, kits and compositions for providing a clinical assessment of prostate cancer |
| EP2882869A4 (en) * | 2012-08-07 | 2016-04-20 | Jackson H M Found Military Med | PROSTATE CANCER GENE EXPRESSION PROFILE |
| US10431326B2 (en) * | 2012-11-20 | 2019-10-01 | Phadia Ab | Method for indicating a presence or non-presence of aggressive prostate cancer |
| SG10201907684PA (en) * | 2013-01-15 | 2019-10-30 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| CN105209636A (zh) * | 2013-03-15 | 2015-12-30 | 麦塔马克基因股份有限公司 | 用于癌症预后的组合物和方法 |
| EP3800266A1 (en) * | 2013-06-13 | 2021-04-07 | University Of South Australia | Methods for detecting prostate cancer |
| AU2014305994B2 (en) * | 2013-08-06 | 2019-02-21 | Exosome Diagnostics, Inc. | Urine biomarker cohorts, gene expression signatures, and methods of use thereof |
| EP3214444A1 (en) | 2016-03-04 | 2017-09-06 | AIT Austrian Institute of Technology GmbH | Prostate cancer diagnostic method and means |
-
2019
- 2019-02-21 EP EP19709298.4A patent/EP3755816B1/en active Active
- 2019-02-21 WO PCT/US2019/018878 patent/WO2019165021A1/en not_active Ceased
- 2019-02-21 KR KR1020207026864A patent/KR102921718B1/ko active Active
- 2019-02-21 ES ES19709298T patent/ES3023842T3/es active Active
- 2019-02-21 KR KR1020267002939A patent/KR20260018206A/ko active Pending
- 2019-02-21 MX MX2020008702A patent/MX2020008702A/es unknown
- 2019-02-21 BR BR112020016989-7A patent/BR112020016989A2/pt unknown
- 2019-02-21 AU AU2019224025A patent/AU2019224025B2/en active Active
- 2019-02-21 CN CN202510096498.4A patent/CN119932188A/zh active Pending
- 2019-02-21 SG SG11202007922XA patent/SG11202007922XA/en unknown
- 2019-02-21 US US16/281,315 patent/US11410748B2/en active Active
- 2019-02-21 EP EP25156901.8A patent/EP4538393A3/en active Pending
- 2019-02-21 CN CN201980027332.XA patent/CN112673115B/zh active Active
- 2019-02-21 CA CA3091647A patent/CA3091647A1/en active Pending
- 2019-02-21 JP JP2020544261A patent/JP7662337B2/ja active Active
- 2019-02-21 PL PL19709298.4T patent/PL3755816T3/pl unknown
- 2019-02-21 DK DK19709298.4T patent/DK3755816T3/da active
-
2020
- 2020-08-17 IL IL276748A patent/IL276748A/en unknown
- 2020-08-20 MX MX2025000449A patent/MX2025000449A/es unknown
-
2022
- 2022-07-26 US US17/815,102 patent/US20230298695A1/en not_active Abandoned
-
2025
- 2025-04-03 JP JP2025061707A patent/JP2025096376A/ja active Pending
- 2025-04-18 US US19/182,880 patent/US20260066046A1/en active Pending
- 2025-09-26 AU AU2025238057A patent/AU2025238057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019224025A1 (en) | 2020-09-10 |
| SG11202007922XA (en) | 2020-09-29 |
| IL276748A (en) | 2020-10-29 |
| WO2019165021A1 (en) | 2019-08-29 |
| CN112673115A (zh) | 2021-04-16 |
| US20260066046A1 (en) | 2026-03-05 |
| JP2021514624A (ja) | 2021-06-17 |
| US20190259471A1 (en) | 2019-08-22 |
| KR20200123450A (ko) | 2020-10-29 |
| EP4538393A2 (en) | 2025-04-16 |
| MX2025000449A (es) | 2025-03-07 |
| PL3755816T3 (pl) | 2025-06-30 |
| JP2025096376A (ja) | 2025-06-26 |
| CN119932188A (zh) | 2025-05-06 |
| KR20260018206A (ko) | 2026-02-06 |
| JP7662337B2 (ja) | 2025-04-15 |
| CA3091647A1 (en) | 2019-08-29 |
| BR112020016989A2 (pt) | 2020-12-29 |
| KR102921718B1 (ko) | 2026-02-03 |
| AU2025238057A1 (en) | 2025-11-27 |
| EP3755816B1 (en) | 2025-02-12 |
| EP4538393A3 (en) | 2025-07-02 |
| EP3755816A1 (en) | 2020-12-30 |
| US11410748B2 (en) | 2022-08-09 |
| DK3755816T3 (da) | 2025-04-28 |
| CN112673115B (zh) | 2025-02-18 |
| US20230298695A1 (en) | 2023-09-21 |
| ES3023842T3 (en) | 2025-06-03 |
| AU2019224025B2 (en) | 2025-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008702A (es) | Metodos para la deteccion y tratamiento del cancer de prostata. | |
| MX2023006766A (es) | Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer. | |
| AU2018329925A8 (en) | Diagnostic and therapeutic methods for cancer | |
| PH12018500322A1 (en) | Methods of treating cancer patients with farnesyltransferase inhibitors | |
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| EP3618914A4 (en) | IMPLANTABLE DEVICES AND METHODS FOR TREATMENT OF BENIGNER PROSTATE HYPERPLASIA (BPH) AND RELATED LOWER URINE TRAIN SYMPTOMS (LUTS) | |
| JOP20190272A1 (ar) | مثبطات kras g12c وطرق لاستخدامها | |
| MX2015011362A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| BR112018007671A2 (pt) | terapia de combinação para tratamento de malignidades | |
| BR112022017508A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| JOP20190199B1 (ar) | استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5 | |
| MX2021002071A (es) | Metodos relacionados con la gravedad y progresion de la lesion premaligna bronquial. | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| BR112017021312A2 (pt) | tratamento de câncer de pulmão com inibidores de glutaminase | |
| MX388084B (es) | Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa. | |
| EA201890968A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| WO2021162981A3 (en) | Methods and compositions for identifying castration resistant neuroendocrine prostate cancer | |
| EA201992721A1 (ru) | Способы получения и применения ингибиторов pde9 | |
| CY1123707T1 (el) | Νεοι αναστολεις καλλικρεϊνης 7 | |
| BR112021020525A2 (pt) | Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação | |
| MX394077B (es) | Metodos para tratar cancer con inhibidores de farnesiltransferasa. | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| EP3648741A4 (en) | TREATMENT OF HYPERPLASTIC TISSUE GROWTH INCLUDING BENEFIT PROSTATE HYPERPLASIA (BPH) BY DIRECT INJECTION OF ANTINEOPLASTIC AGENT | |
| EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови |